… Pharmacology of oxaliplatin in solid tumor patients with … Dose-escalating and pharmacological
study of oxaliplatin in … of the national cancer institute organ dysfunction working group. …

… BM, Ivy P National Cancer Institute Organ Dysfunction Working Group. Dose-escalating and
pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a …

… Pharmacological assays of plasma irinotecan and SN-38 … studies of oxaliplatin in renal failure
patients with creatinine … those with liver metastases (and/or impaired liver function) should …

… Baseline liver function appeared consistent across the cohorts with similar rates of … PK
studies performed in cancer patients [26–32]. For example, oxaliplatin and imatinib PK studies …

… TMA is associated with poor outcomes and does not have an established treatment. Mild …
to oxaliplatin, as well as TMA.71, 72, 73, 74 Another notable complication of oxaliplatin is …

… patients with impaired hepatic and/or renal function due to favorable pharmacokinetics [12–14].
Classical chemotherapy regimens have traditionally achieved very poor … phase 2 study of …

… Despite these new approaches, the prognosis of CRC remains poor and a better understanding
… Pharmacological approaches to alleviating oxaliplatin-induced neurotoxicity have also …

… involvement by colorectal cancer, oxaliplatin combinations [1… Pharmacological studies
advocate a dose reduction with 30% … at therapeutic levels and not dependent on liver function [16]. …

… The pharmacologic activity of oxaliplatin is influenced by several variables. After an … to
achieve greater tumor kill. In these studies, we sought to establish oxaliplatin exposure–response …

… Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with
impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J …